Material Safety Data Sheet Section 1. Identification of the substance Product Name: 3-Bromo-2-(chloromethyl)pyridine Synonyms: Section 2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section 3. Composition/information on ingredients. Ingredient name: 3-Bromo-2-(chloromethyl)pyridine CAS number: 122851-69-8 Section 4. First aid measures Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section 5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section 6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution: Wear approved mask/respirator Hand precaution: Wear suitable gloves/gauntlets Skin protection: Wear suitable protective clothing Eye protection: Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section 7. Handling and storage Handling: This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels, refrigerated. Storage: Section 8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section 9. Physical and chemical properties Appearance: Not specified Boiling point: No data No data Melting point: Flash point: No data Density: No data Molecular formula: C6H5BrClN Molecular weight: 206.5 Section 10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide. Section 11. Toxicological information No data. Section 12. Ecological information No data. Section 13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section 14. Transportation information Non-harzardous for air and ground transportation. Section 15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313.
[EN] CRYSTAL FORM OF PYRIMIDO FIVE-MEMBERED NITROGEN HETEROCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR [FR] FORME CRISTALLINE D'UN DÉRIVÉ PYRIMIDO-HÉTÉROCYCLIQUE AZOTÉ À CINQ CHAÎNONS ET SON PROCÉDÉ DE PRÉPARATION [ZH] 一种嘧啶并五元氮杂环类衍生物的晶型及其制备方法
[EN] SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ DE PIPÉRIDINE SUBSTITUÉE ET SON UTILISATION
申请人:TAKEDA PHARMACEUTICALS CO
公开号:WO2017135306A1
公开(公告)日:2017-08-10
Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE
申请人:Carson Matthew William
公开号:US20100069425A1
公开(公告)日:2010-03-18
The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
TAK-925, a potent, selective, and brain-penetrant orexin 2 receptor (OX2R) agonist, [methyl (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate, 16], was identified through the optimization of compound 2, which was discovered by a high throughput screening (HTS) campaign. Subcutaneous administration of compound 16 produced wake-promoting effects in mice
TAK-925,一种强效、选择性和脑渗透性食欲素 2 受体 (OX2R) 激动剂,[甲基 (2 R ,3 S )-3-((甲基磺酰基)氨基)-2-(((顺式-4-苯基环己基)oxy)methyl)piperidine-1-carboxylate, 16 ],是通过优化化合物2鉴定的,该化合物是通过高通量筛选 (HTS) 活动发现的。化合物16的皮下给药在小鼠睡眠阶段产生了促醒作用。正在开发用于治疗发作性睡病和其他相关疾病的化合物16 (TAK-925)。
PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF
申请人:Tuojie Biotech (Shanghai) Co., Ltd.
公开号:EP3889153A1
公开(公告)日:2021-10-06
The present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative, a preparation method therefor, and the medical uses thereof. Particularly, the present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, and the uses thereof as a SHP2 inhibitor for use in the prevention and/or treatment of tumor or cancer, wherein each substituent in the general formula (I) is as defined in the description.